Clinical Trials
14 trialsNCT07169552 2025-12-17
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
HC Biopharma Inc.
Phase 2 Recruiting
NCT05466149 2025-11-19
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Allist Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT07181499 2025-09-30
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Betta Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06672068 2024-12-30
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
TYK Medicines, Inc
Phase 2 Not yet recruiting
NCT03318939 2024-04-03
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT05651269 2022-12-15
Milciclib in Combination With Gemcitabine in Advanced NSCLC
Tiziana Life Sciences LTD
Phase 2 Unknown
NCT05117658 2022-08-04
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT03812809 2022-05-19
A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive
Beta Pharma, Inc.
Phase 2 Completed
NCT05065398 2022-01-21
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
Shanghai Henlius Biotech
Phase 2 Unknown
NCT04044170 2020-11-17
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Hanmi Pharmaceutical Company Limited
Phase 2 Terminated
NCT02976116 2019-11-15
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT00874848 2016-11-29
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
HiberCell, Inc.
Phase 2 Completed
NCT00655161 2014-01-29
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
GlobeImmune
Phase 2 Completed
NCT00283634 2011-02-17
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated